Conference abstractPublished 2 Jul 2012
Treatment with AS101 sensitizes acute myeloid leukemia cells (AML) to chemotherapy by disrupting the interaction between the integrin VLA-4 and Fibronectin: Mechanisms of action and clinical applications
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Bone marrow minimal residual disease (MRD) causes relapse after chemotherapy in patients with acute myelogenous leukemia (AML) due to acquired drug resistance - this is induced by the attachment of the integrin receptor VLA-4 on leukemic cells to its ligand fibronectin (FN) on bone marrow stromal cells. We show that the non toxic compound AS101, previously shown to exert anti tumoral effects in-vitro and in-vivo, sensitizes AML cells to ARA-C only when leukemic cells are plated on FN but not on BSA-coated plates. This was associated with a significant decrease in pAkt and Bcl-2. The sensitizing effect of AS101 was also correlated with the ability of AS101 to deactivate VLA on AML cells. In a model of SCID mice implanted with leukemic cells either from established AML cell lines or with leukemic cells expressing high VLA-4, obtained from AML patients, co- treatment with AS101 and chemotherapy significantly increased mice survival while chemotherapy alone exerted only a modest effect. Furthermore, the combined treatment resulted in the elimination of leukemic cells from all organs tested. Moreover, mice transplanted with AML cells that express low VLA-4, considerably reacted to chemotherapy alone as expressed by increased survival, while co-treatment with AS101 resulted in similar effects. Importantly, AS101 increases migration of leukemic cells expressing high VLA-4 from the Bone-Marrow to the peripheral blood enabling their sensitization to chemotherapy. We propose that treatment with AS101 currently used in treatment of cancer patients, combined with chemotherapy, has a potential to eradicate MRD and prolong survival of AML patients
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Molecular Biomarkers & Diagnosis
- SubjectGenetics & Molecular Biology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Sredni Benjamin”
- BylineArticles whose byline prints “Kalechman Yona”
- BylineArticles whose byline prints “Barda-Saad Mira”
- BylineArticles whose byline prints “Noy Elad”
- BylineArticles whose byline prints “Skornik Itay”
- BylineArticles whose byline prints “Bazar Adi Bazar”
